News

News

December 16, 2005

New diagnostic assay for pancreatic cancer reported in Journal of Clinical Oncology

December 15, 2005

Immunomedics reports preclinical results on new therapeutic

- Properties of New Immunotoxin Described in Blood Article -

December 12, 2005

Immunomedics reports humanized anti-CD20 antibody appears safe and active in non-Hodgki’s lymphoma

- Initial Clinical Results Presented at the 47th Annual Meeting of American Society of Hematology (ASH) -

December 9, 2005

Immunomedics reports updated clinical results of Epratuzumab-Rituximab combination in lymphoma

- Abstract Published at American Society of Hematology (ASH) 47th Annual Meeting -

December 7, 2005

Immunomedics announces outcome of 2005 annual meeting of shareholders

November 28, 2005

Immunomedics describes alleviate trials design

- To be presented at Lazard Capital Markets Annual Life Sciences Conference -

November 15, 2005

Immunomedics reports updated clinical results for epratuzumab in SjÖgren’ Syndrome

November 7, 2005

Immunomedics announces first quarter fiscal 2006 results

November 3, 2005

Immunomedics to present at Rodman & Renshaw Techvest 7th annual healthcare conference

October 18, 2005

Immunomedics resale shelf registration statement declared effective

September 19, 2005

Immunomedics files resale shelf registration statement on behalf of certain security holders

September 8, 2005

Immunomedics announces fiscal 2005 results

September 6, 2005

Immunomedics announces positive ruling from Nasdaq appeal panel

September 2, 2005

Immunomedics announces change in senior management

August 19, 2005

Immunomedics announces approval of two proposals at special meeting of stockholders

July 5, 2005

Immunomedics commences exchange offer for 5% senior convertible notes and common stock warrants

June 20, 2005

David M. Goldenberg receives highest award from Society of Nuclear Medicine

June 16, 2005

Immunomedics awarded U.S. and Australian patents for autoimmune disease therapy with CD22 antibodies

June 14, 2005

Immunomedics to appeal Nasdaq ruling and files preliminary proxy material for stockholder meeting

June 10, 2005

Immunomedics reports initial clinical results for Epratuzumab in SjÖren’s syndrome

June 1, 2005

Immunomedics initiates two pivotal Phase III trials in lupus

May 26, 2005

Immunomedics announces conference call and webcast

May 25, 2005

Immunomedics to present at the American Society of Clinical Oncology annual meeting

May 5, 2005

Immunomedics announces third quarter fiscal 2005 results

May 2, 2005

Immunomedics completes $37 million financing

April 28, 2005

Immunomedics to present at Rodman & Renshaw Techvest 2nd annual Global Healthcare Conference

April 27, 2005

Immunomedics announces $36 million senior convertible notes and warrant offering

March 28, 2005

Immunomedics’ humanized anti-cd20 antibody effective in severe lupus

February 4, 2005

Immunomedics announces second quarter fiscal 2005 results

January 19, 2005

Immunomedics announces Canadian approval of Leukoscan ©

January 11, 2005

Immunomedics elects Don C. Stark to board of directors

January 5, 2005

Immunomedics Epratuzumab on FDA fast track for lupus therapy